Eurocine Vaccines´ newly added HSV-2 vaccine candidate gains patent protection in South Korea
Eurocine Vaccines has received a Notice of Decision to Grant from the Korean Intellectual Property Office, covering inventions relevant for the newly added vaccine candidate…
Eurocine Vaccines discloses year-end report for the fiscal year 2021/2022
Eurocine Vaccines AB (publ) (”Eurocine Vaccines) hereby discloses the year-end report for the fiscal year 2021/2022. Below is a summary of the report. The full…
Disclosure notice in Eurocine Vaccines
Eurocine Vaccines AB hereby announces that Flerie Invest AB has acquired shares in the company and now holds more than 15 % of the shares.…
Eurocine Vaccines outlines a strategic development plan for its newly added therapeutic HSV-2 vaccine candidate
Expanding its portfolio, Eurocine Vaccines adds considerable value by the new HSV-2 vaccine candidate, which holds significant market potential. Currently, Herpes Simplex Virus Type 2,…
Eurocine Vaccines expands its portfolio with a therapeutic HSV-2 vaccine candidate
Eurocine Vaccines AB ("Eurocine Vaccines") hereby announces that the company has entered into a research and collaboration agreement with Redbiotec AG ("Redbiotec"). The agreement gives…
Eurocine Vaccines publishes interim report for July 2021 – March 2022
Eurocine Vaccines AB (publ) (”Eurocine Vaccines) hereby publishes the interim report for July 2021 to December 2022. Below is a summary of the report. The…
Eurocine Vaccines publishes CEO interview
CEO Hans Arwidsson discussed the vaccine portfolio, the progress with the chlamydia vaccine candidate, and the future plans for the business in an interview conducted…
Eurocine Vaccines publishes half-year report for July – December 2021
Eurocine Vaccines AB (“Eurocine Vaccines”) hereby publishes the half-year report for July to December 2021. Below is a summary of the report. The full report…
Eurocine Vaccines enters into agreement with Flerie Invest to secure exercise of warrants of series TO 4
Eurocine Vaccines AB (“Eurocine Vaccines” or “the Company”) announces today that the Company has agreed to secure warrants of series TO 4 (“TO 4”) with…
Eurocine Vaccines resolves on scientific advice with the Swedish Medical Products Agency ahead of clinical trial application
The Board of Directors of Eurocine Vaccines has resolved to request scientific advice from the Swedish Medical Products Agency ahead of submitting the clinical trial…